已收盘 05-08 16:00:00 美东时间
+0.030
+0.23%
BREAKINGVIEWS-India's overseas M&A rush risks official ire The author is a Reuters Breakingviews columnist. The opinions expressed are her own. By Shritama Bose MUMBAI, May 8 (Reuters Breakingviews) - Sun Pharma's $12 bln offer for US-based Organon follows Tata Motors' $4 bln bid for Iveco's trucks
05-08 09:56
Organon SVP, Corporate Controller Lynette Holzbaur acquires shares worth $353,080.54 Organon reported an open-market purchase of 26,448 shares by Lynette Holzbaur, SVP and Corporate Controller. Shares were bought at USD 13.35 each. Holzbaur’s direct holding rose to 52,850 shares. Disclaimer: This ne
05-07 22:03
MEDIA-Sun Pharma explores funding mix for $12 billion Organon deal - Bloomberg News -- Source link: https://tinyurl.com/2bl5hwaj -- Note: Reuters has not verified this story and does not vouch for its accuracy (( globalnewsmonitoring@thomsonreuters.com ))
05-06 09:08
华盛资讯5月4日讯,Organon & Co.公布2026财年Q1业绩,公司Q1营收14.60亿美元,同比下降3.5%,归母净利润1.46亿美元,同比增长67.8%。
05-04 21:01
Federal Reserve Governor Michael Barr said trouble in the fast-growing private credit market could spill into the broader financial system through what he described as “psychological contagion,” renew...
05-04 00:32
Treasury Secretary Scott Bessent said the United States is tightening economic and financial pressure on Iran to the point where Tehran’s leadership may eventually be forced to yield. “We are running ...
05-04 00:15
Here's a list of key deals reported across sectors this week: Esperion Therapeutics (ESPR) shares jumped about 57% in premarket trading on Friday after the drugmaker agreed to be acquired by healthcar...
05-03 23:15
Major M&A deals this week include: Eli Lilly buys Profluent for $2.2 billion, Lazard buys Campbell Lutyens, FreshRealm bankruptcy.
05-02 02:35
Organon (NYSE:OGN) reported quarterly earnings of $0.71 per share which missed the analyst consensus estimate of $0.83 by 14.46 percent. This is a 30.39 percent decrease over earnings of $1.02 per share from the same
04-30 20:08
今日重点评级关注:HC Wainwright & Co.:维持Protara Therapeutics"买入"评级,目标价从23美元升至27美元;BTIG:维持Black Diamond Therapeutic"买入"评级,目标价从10美元升至11美元
04-30 19:24